Literature DB >> 26451010

Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes.

Martin Tauschmann1, Hood Thabit1, Lalantha Leelarathna1, Daniela Elleri1, Janet M Allen1, Alexandra Lubina-Solomon2, Marietta Stadler3, Emma Walkinshaw2, Ahmed Iqbal2, Pratik Choudhary3, Malgorzata E Wilinska1, Simon R Heller2, Stephanie A Amiel3, Mark L Evans1, David B Dunger1, Roman Hovorka4.   

Abstract

Entities:  

Keywords:  closed-loop insulin delivery; glycemic control; home study; predictive factors; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26451010      PMCID: PMC4667301          DOI: 10.1177/1932296815604439

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


× No keyword cloud information.
Unsupervised free-living overnight home use of closed-loop insulin delivery is feasible, safe, and effective in adolescents[1] and adults[2] with type 1 diabetes, but outcomes vary between individuals. Understanding factors influencing glucose outcomes may help to identify vulnerable populations, guide design of future studies, and lead to enhanced control algorithms. To explore associations between demographic characteristics, the use of closed-loop and glucose performance, we pooled data from 2 multicenter trials, 1 involving adolescents,[1] and 1 involving adults[2] with type 1 diabetes. Both studies adopted an open-label, cross-over, randomized controlled study design. Participants were randomly assigned to 4 (adults) or 3 (adolescents) weeks of sensor-augmented pump therapy with or without overnight closed-loop. An identical model-predictive-control algorithm was used in both studies.[3] Participants were instructed to start the system at home after their evening meal and to discontinue it before breakfast the next morning. Detailed methods and results are reported elsewhere.[1-2] In the present work, Pearson’s correlation coefficients quantified the relationship between baseline demographic factors (age, BMI, HbA1c, total daily dose), participant-level utility characteristics (average duration of closed-loop application, average start time of closed-loop) and closed-loop outcomes between midnight and 08:00 (mean glucose, time in target between 70 and 145 mg/dl, time below 70 mg/dl) (Table 1). Age and time below target were rank-normal transformed. Associations with gender were evaluated applying Spearman correlation. Multiple linear regression analysis quantified the amount of explained variability of closed-loop outcomes using demographic and utility characteristics.
Table 1.

Pearson’s Correlation Coefficients Between Closed-Loop Outcomes and Demographic and Utility Characteristics (N = 40).

AgeBMIHbA1cTotal daily doseDuration of closed-loop applicationTime of closed-loop start
Mean glucose (P value).17 (.294).10 (.550).52 (.001)−.25 (.119)−.20 (.209).25 (.117)
Time in target 70-145 mg/dl (P value)−.33 (.038)−.24 (.129)−.26 (.101).27 (.097).30 (.064)−.30 (.064)
Time below 70 mg/dl (P value).04 (.786).14 (.386)−.43 (.006).06 (.702)−.12 (.473)−.25 (.127)
Pearson’s Correlation Coefficients Between Closed-Loop Outcomes and Demographic and Utility Characteristics (N = 40). Forty participants completed the studies, including 24 adults (age 43 ± 12 years [mean ± SD]; HbA1C 64.9 ± 8.9mmol/mol, 8.1 ± 0.8%; BMI 26.0 ± 3.5kg/m2; total daily insulin dose 0.5 ± 0.1U/kg/day) and 16 adolescents (age 15.6 ± 2.1 years; HbA1C 63.9 ± 9.4mmol/mol, 8.0 ± 0.9%; BMI 22.4 ± 3.7kg/m2; total daily insulin dose 0.8 ± 0.2U/kg/day). Data on 866 closed-loop nights were analyzed. HbA1c at baseline was associated with mean glucose during closed-loop nights (r = .52, P = .001) and time with hypoglycemia (r = –.43, P = .006), but not time in target (r = –.26, P = .101). Early closed-loop start and longer closed-loop application tended to increase time in target (P = .064). There was an age-associated reduction in time in target (r = –.33, P = .038), perhaps reflecting the association between older age and shorter period of closed-loop use (r = –.58, P < .001). Of the variance in mean glucose, 33% was explained by the regression model (P = .028), with HbA1c as the only significant predictor (P = .001). For time below target, the explained variance was 36% (P = .017); earlier closed-loop start time (P = .017) and HbA1c (P = .008) were significant predictors. Only 20% of variance in time in target was explained by the regression model. The strength of the current work is that the data were collected during free-living unsupervised home closed-loop use. Weaknesses include that we did not capture at all or with low confidence other potentially influential factors such as socioeconomic and educational status, exercise patterns, and meal size and composition. In conclusion, in adolescents and adults with type 1 diabetes undergoing overnight closed-loop, baseline HbA1c is correlated with mean overnight glucose but not time in target range. Despite closed-loop, a lower HbA1c level remains a risk factor for nocturnal hypoglycemia. Improved time in target may be observed if overnight closed-loop is started earlier and applied for longer.
  3 in total

1.  Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes.

Authors:  Daniela Elleri; Janet M Allen; Martina Biagioni; Kavita Kumareswaran; Lalantha Leelarathna; Karen Caldwell; Marianna Nodale; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger; Roman Hovorka
Journal:  Pediatr Diabetes       Date:  2012-07-23       Impact factor: 4.866

2.  Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial.

Authors:  Roman Hovorka; Daniela Elleri; Hood Thabit; Janet M Allen; Lalantha Leelarathna; Ranna El-Khairi; Kavita Kumareswaran; Karen Caldwell; Peter Calhoun; Craig Kollman; Helen R Murphy; Carlo L Acerini; Malgorzata E Wilinska; Marianna Nodale; David B Dunger
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

3.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.

Authors:  Hood Thabit; Alexandra Lubina-Solomon; Marietta Stadler; Lalantha Leelarathna; Emma Walkinshaw; Andrew Pernet; Janet M Allen; Ahmed Iqbal; Pratik Choudhary; Kavita Kumareswaran; Marianna Nodale; Chloe Nisbet; Malgorzata E Wilinska; Katharine D Barnard; David B Dunger; Simon R Heller; Stephanie A Amiel; Mark L Evans; Roman Hovorka
Journal:  Lancet Diabetes Endocrinol       Date:  2014-06-16       Impact factor: 32.069

  3 in total
  2 in total

1.  Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.

Authors:  Stacey M Anderson; Bruce A Buckingham; Marc D Breton; Jessica L Robic; Charlotte L Barnett; Christian A Wakeman; Mary C Oliveri; Sue A Brown; Trang T Ly; Paula K Clinton; Liana J Hsu; Ryan S Kingman; Lisa M Norlander; Sarah E Loebner; Suzette Reuschel-DiVirglio; Boris P Kovatchev
Journal:  Diabetes Technol Ther       Date:  2019-05-16       Impact factor: 6.118

2.  Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery.

Authors:  Ana Gianini; Jana Suklan; Brigita Skela-Savič; Simona Klemencic; Tadej Battelino; Klemen Dovc; Nataša Bratina
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.